Metacognitive Therapy for Obsessive-Compulsive Disorder (MCTOCD)

Northeast Normal University

Status: Enrolling

Conditions: Obsessive-Compulsive Disorder

Treatments: Behavioral: Metacognitive Therapy; Other: General mental health promotion

Study type: Interventional

Funder types: Other

Identifiers

NCT06466057

NENU2023032

Details and patient eligibility

About

The goal of this clinical trial is to learn if metacognitive therapy can be effective in a Chinese sample of obsessive compulsive disorder (OCD) . The main questions it aims to answer are:

Can metacognitive therapy significantly reduce participants' levels of obsessive-compulsive symptoms? Can metacognitive therapy significantly improve participants' metacognitive adaptations?

The researchers will compare metacognitive therapy to a control condition without psychotherapy to see if metacognitive therapy is effective in treating OCD.

Participants will:

Receive the metacognitive therapy intervention or under control conditions for 8 to 15 weeks.

Be assessed for symptoms and metacognitive beliefs at pre-intervention, post-intervention and 12 weeks post-intervention

Full description

This study will be a randomised controlled clinical trial. Participants who meet the enrolment criteria will be randomised into an experimental group and a control group. Participants in the experimental group will receive 8-15 weeks of metacognitive therapy, while participants in the control group will receive the same amount of time of regular treatment without psychotherapy components.

The researchers will assess participants' obsessive-compulsive symptoms and metacognitive levels before, after, and 12 weeks after the intervention. Assessment measures will be the Yale Brown Obsessive-Compulsive Scale (Y-BOCS) and the Metacognition Questionnaire (MCQ-30).

By comparing the assessment results of the two groups of participants, conclusions will be drawn as to whether metacognitive therapy can have a positive effect on a Chinese OCD sample.

Enrollment: 80 estimated patients

Sex: All

Ages: 12 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• two psychiatrists with the title of Deputy Chief Physician or above jointly determine that the above diagnostic criteria were met
• education level of junior high school or above, without mental retardation or audio-visual disorders
• participation in the study is voluntary, and the informed consent is signed by the patient or his/her guardian

Exclusion criteria

• loss of or insufficient self-awareness, the presence of hallucinations, delusions, and other psychotic symptoms
• the presence of severe depression, or self-inflicted suicidal attempts and behaviors
• the presence of a history of alcohol or drug abuse
• refusal of psychotherapy, or the ineffectiveness of those who had been involved in a full course of psychotherapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

80 participants in 2 patient groups, including a placebo group

Metacognitive Therapy

Experimental group

Description:

Intervention using metacognitive therapy, with sessions set for 8-15 weeks of 1-2 weekly psychotherapeutic dialogue.

Treatment:

Behavioral: Metacognitive Therapy

Control Condition

Placebo Comparator group

Description:

Do not receive any additional psychotherapy in addition to conventional treatment.

Treatment:

Other: General mental health promotion